CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion President & CEO acquired 8,756 shares (option exercise)
- 4 Open-market buy President & CEO bought 2,994 shares at an average $7.05 ($21,115)
- 4 Open-market sale Chief Business Officer sold 6,000 shares at an average $9.50 ($57,005)
- 4 Exercise or conversion Chief Business Officer acquired 8,500 shares (option exercise)
- 4 Exercise or conversion Director acquired 37,333 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion Interim CEO acquired 38,866 shares (option exercise)
- 4 Exercise or conversion Interim CEO acquired 3,307 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 10 of 14 · 271 filings